Cardiovascular collaboration
Cryptome Pharmaceuticals has signed a memorandum of understanding with the University of Queensland's Institute for Molecular Biosciences (IMB) to collaborate on the identification of potential therapeutics for cardiovascular disease.
The IMB will provide Cryptome with high value compound libraries, which Cryptome will screen for potential activity using its proprietary Cryptomics platform technology. The Cryptomics drug discovery platform is based on finding small protein fragments with previously undiscovered therapeutic activities. These fragments are generated, screened and identified using the Cryptomics systematic high-throughput approach.
L'Oréal-UNESCO For Women In Science Fellows announced for ANZ
This year's program honours four women who are reshaping what leadership in research looks...
Peter Beattie appointed Chair of Brandon BioCatalyst
Brandon BioCatalyst has announced new board appointments to continue the scaling of Australian...
Virologist receives GSK Award for AI-based disease detection
Professor Edward Holmes has received the 2025 GSK Award for Research Excellence for his use of...
